VVOS — Vivos Therapeutics, Inc.

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1716166 ·
Last close
$0.65
Market Cap
$8.99M
52W High
$1.54
52W Low
$0.55
ADV30
241,163
Next earnings
Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 5,141,000 3,059,000 -6,615,000 -7,751,000 25,043,000 2,110,000 26,310,000
Dec 2025 3,824,000 2,988,000 -6,382,000 -6,954,000 25,152,000 2,029,000 26,702,000
Sep 2025 6,783,000 3,937,000 -4,734,000 -5,400,000 25,644,000 3,087,000 23,112,000
Jun 2025 3,820,000 2,110,000 -4,865,000 -5,013,000 26,033,000 4,402,000 21,450,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-15,263,000
Investing CF
$-7,526,000
Financing CF
$18,558,000
CapEx
$-2,589,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-1.89
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-125,357,000
Inventory
Receivables
$1,581,000
ST Investments
EBIT TTM
$-19,899,000
Pretax Income TTM
$-21,231,000
Interest Exp TTM
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$19,568,000
EBITDA
$-21,005,000
Free Cash Flow
$-10,076,375
Enterprise Value
$18,504,706
Total Cash
$2,110,000
Total Debt
$12,268,000
Shares Out
13,894,600
Trailing EPS
$-2.08
Book Value
$0.31
ROE
-1599.8%
ROA
-77.7%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 17,443,000 -19,894,000 -21,230,000 25,152,000 26,702,000 -15,263,000
Dec 2024 15,031,000 -11,171,000 -11,136,000 15,284,000 7,330,000 -12,691,000
Dec 2023 13,801,000 -17,296,000 -13,583,000 10,730,000 10,319,000 -11,946,000
Dec 2022 16,024,000 -25,031,000 -23,845,000 13,720,000 8,919,000 -19,587,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.35

Peers — same industry

TickerNameMarket CapLastDaily %
ALRTF ALR Technologies SG Ltd. $9.68M $0.01
TNON Tenon Medical, Inc. $8.01M $0.69
USAQ QHSLab, Inc. $7.82M $0.52
NXL Nexalin Technology, Inc. $10.34M $0.48
SINT Sintx Technologies, Inc. $10.50M $2.43

News headlines (Yahoo Finance, 1h cache)

Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update
2026-05-20 20:10 · Yahoo
Plus Therapeutics (PSTV) Reports Q1 Loss, Tops Revenue Estimates
2026-05-15 21:20 · Yahoo
New to The Street to Broadcast Tonight on Bloomberg at 6:30 PM EST - Show #744 Featuring Virtuix Holdings (NASDAQ:VTIX), Neonc Technologies Holdings (NASDAQ:NTHI), Medicus Pharma (NASDAQ:MDCX), YY Gro
2026-04-18 14:00 · Yahoo
Vivos Therapeutics Inc (VVOS) Q4 2025 Earnings Call Highlights: Revenue Growth Amid Strategic ...
2026-04-16 07:01 · Yahoo
Vivos Therapeutics Reports Full Year 2025 Financial Results
2026-04-15 20:20 · Yahoo
Vivos Therapeutics Schedules Release of Full Year 2025 Financial Results and Conference Call
2026-04-15 12:45 · Yahoo
Vivos Therapeutics, Inc. Q4 2025 Earnings Call Summary
2026-04-15 12:30 · Yahoo
New to The Street to Broadcast on Fox Business on Monday, April 13, Featuring Virtuix Holdings (NASDAQ:VTIX), Medicus Pharma (NASDAQ:MDCX), YY Group Holdings (NASDAQ:YYGH), Vivos Therapeutics (NASDAQ:
2026-04-11 16:30 · Yahoo
New to The Street Broadcasts on Bloomberg Television at 6:30 PM EST Featuring IGC Pharma (IGC), Vivos Therapeutics (VVOS), Acurx Pharmaceuticals (ACXP), and Equinox Gold (EQX)
2026-04-11 13:35 · Yahoo
Vivos Therapeutics Completes Private Placement with Existing Private Equity Investor, New Seneca Partners
2026-04-07 12:45 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.